vs
Piedmont Realty Trust, Inc.（PDM）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Piedmont Realty Trust, Inc.的1.4倍（$197.9M vs $143.3M），REPLIGEN CORP净利率更高（6.7% vs -31.4%，领先38.1%），REPLIGEN CORP同比增速更快（13.6% vs 0.4%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 0.0%）
Piedmont Realty Trust是一家公开上市的房地产投资信托（REIT），主要持有、运营和投资美国高增长大都会区的优质写字楼资产，服务科技、专业服务、医疗等多个行业的企业租户，通过战略资产管理和投资组合优化为利益相关方提供稳定长期回报。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
PDM vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.4倍
$143.3M
营收增速更快
RGEN
高出13.2%
0.4%
净利率更高
RGEN
高出38.1%
-31.4%
两年增速更快
RGEN
近两年复合增速
0.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.3M | $197.9M |
| 净利润 | $-45.0M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | — | 9.0% |
| 净利率 | -31.4% | 6.7% |
| 营收同比 | 0.4% | 13.6% |
| 净利润同比 | -27.9% | 143.9% |
| 每股收益（稀释后） | $-0.10 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PDMRGEN
| Q1 26 | $143.3M | — | ||
| Q4 25 | $142.9M | $197.9M | ||
| Q3 25 | $139.2M | $188.8M | ||
| Q2 25 | $140.3M | $182.4M | ||
| Q1 25 | $142.7M | $169.2M | ||
| Q4 24 | $143.2M | $174.1M | ||
| Q3 24 | $139.3M | $154.9M | ||
| Q2 24 | $143.3M | $154.1M |
净利润PDMRGEN
| Q1 26 | $-45.0M | — | ||
| Q4 25 | $-43.2M | $13.3M | ||
| Q3 25 | $-13.5M | $14.9M | ||
| Q2 25 | $-16.8M | $14.9M | ||
| Q1 25 | $-10.1M | $5.8M | ||
| Q4 24 | $-30.0M | $-30.3M | ||
| Q3 24 | $-11.5M | $-654.0K | ||
| Q2 24 | $-9.8M | $3.3M |
毛利率PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% |
营业利润率PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | — | 1.0% |
净利率PDMRGEN
| Q1 26 | -31.4% | — | ||
| Q4 25 | -30.3% | 6.7% | ||
| Q3 25 | -9.7% | 7.9% | ||
| Q2 25 | -12.0% | 8.2% | ||
| Q1 25 | -7.1% | 3.4% | ||
| Q4 24 | -20.9% | -17.4% | ||
| Q3 24 | -8.3% | -0.4% | ||
| Q2 24 | -6.8% | 2.2% |
每股收益（稀释后）PDMRGEN
| Q1 26 | $-0.10 | — | ||
| Q4 25 | $-0.34 | $0.24 | ||
| Q3 25 | $-0.11 | $0.26 | ||
| Q2 25 | $-0.14 | $0.26 | ||
| Q1 25 | $-0.08 | $0.10 | ||
| Q4 24 | $-0.25 | $-0.55 | ||
| Q3 24 | $-0.09 | $-0.01 | ||
| Q2 24 | $-0.08 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $1.5B | $2.1B |
| 总资产 | $4.0B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资PDMRGEN
| Q1 26 | $2.3M | — | ||
| Q4 25 | $731.0K | $767.6M | ||
| Q3 25 | $3.0M | $748.7M | ||
| Q2 25 | $3.3M | $708.9M | ||
| Q1 25 | $2.9M | $697.2M | ||
| Q4 24 | $109.6M | $757.4M | ||
| Q3 24 | $133.6M | $784.0M | ||
| Q2 24 | $138.5M | $809.1M |
总债务PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | $542.2M | ||
| Q3 25 | $2.2B | $537.9M | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | $525.6M | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
股东权益PDMRGEN
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $2.1B | ||
| Q3 25 | $1.5B | $2.1B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.6B | $2.0B | ||
| Q3 24 | $1.6B | $2.0B | ||
| Q2 24 | $1.7B | $2.0B |
总资产PDMRGEN
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $2.9B | ||
| Q3 25 | $4.0B | $2.9B | ||
| Q2 25 | $4.0B | $2.9B | ||
| Q1 25 | $4.0B | $2.9B | ||
| Q4 24 | $4.1B | $2.8B | ||
| Q3 24 | $4.1B | $2.8B | ||
| Q2 24 | $4.2B | $2.9B |
负债/权益比PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | 1.49× | 0.26× | ||
| Q3 25 | 1.43× | 0.26× | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.40× | 0.27× | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | 110.3% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | $140.6M | $25.7M | ||
| Q3 25 | $35.8M | $48.1M | ||
| Q2 25 | $50.1M | $28.6M | ||
| Q1 25 | $3.7M | $15.0M | ||
| Q4 24 | $198.1M | $39.2M | ||
| Q3 24 | $42.9M | $49.3M | ||
| Q2 24 | $66.8M | $42.2M |
自由现金流PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M |
自由现金流率PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% |
资本支出强度PDMRGEN
| Q1 26 | 110.3% | — | ||
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% |
现金转化率PDMRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
